RxDoctor Payments Data

Richard Mandel, DO

Family Medicine · Philadelphia, PANPI 1346271244

Payments from drug & device makers

$9,730in general payments, 2019–2025

Across 569 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Pfizer$866
  • Novo Nordisk$817
  • Lilly USA, LLC$559
  • Abbott$492
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$9,711100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,730 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$153,926
Medicare patients
418
Services billed
2,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$111,684
FarxigaDapagliflozin Propanediol139$104,210
JanuviaSitagliptin Phosphate70$77,191
JardianceEmpagliflozin43$60,169
MounjaroTirzepatide46$51,689
OzempicSemaglutide37$46,209
XareltoRivaroxaban15$26,039
TradjentaLinagliptin19$25,706
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,951
TrulicityDulaglutide14$12,463
Spiriva RespimatTiotropium Bromide19$10,357
Tresiba Flextouch U-100Insulin Degludec14$10,235
SymbicortBudesonide/Formoterol Fumarate33$9,979
Atorvastatin Calcium656$9,424
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$9,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$1,698$114,189172 claims
PfizerEliquis$866$111,684102 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat$293$105,45592 claims
MerckJanuvia$200$77,19170 claims
Lilly USA, LLCMounjaro, Trulicity$559$64,15260 claims
Novo NordiskOzempic$817$46,20937 claims
Johnson & JohnsonXarelto$106$26,03915 claims
GSKTrelegy Ellipta$386$13,95118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →